For the quarter ending 2026-01-31, PBSV had $2,384,406 increase in cash & cash equivalents over the period. -$392,550 in free cash flow.
| Cash Flow | 2026-01-31 | 2025-10-31 | 2025-07-31 |
|---|---|---|---|
| Net income | -32,860 | 100,463 | - |
| Net loss | - | - | -100,361 |
| Gain on disposition of vehicle | 7,000 | - | - |
| Stock-based compensation | 8,619 | 4,399 | 30,680 |
| Depreciation and amortization | 14,796 | 15,817 | 44,049 |
| Amortization of operating lease right-of-use | 29,388 | 43,359 | 125,850 |
| Reinvested interests | 83,346 | -148,220 | 185,746 |
| Increase in accounts receivable | 277,116 | 347,839 | -551,482 |
| Decrease (increase) in prepaids and other assets | - | -308,312 | - |
| Decrease in other assets | -67,619 | - | 27,903 |
| Decrease in liabilities | -148,056 | 79,597 | -932,603 |
| Net cash provided by (used in) operating activities | -390,139 | 279,666 | -494,552 |
| Acquisition of property and equipment | 2,411 | 350 | 6,294 |
| Proceeds from sale of vehicle | 7,000 | - | - |
| Marketable securities settlement (investment), net | - | - | 603,432 |
| Marketable securities investments, net | 2,762,155 | -1,459,747 | - |
| Net cash provided by (used in) investing activities | 2,766,744 | -856,665 | -609,726 |
| Repurchase of common stock | 1,681 | 9,202 | 22,241 |
| Cash dividends paid to shareholders | - | 0 | 1,719,918 |
| Cash used in financing activities | -1,681 | -9,202 | -1,742,159 |
| Effect of exchange rate changes on cash | 9,482 | 7,661 | 36,833 |
| Net increase (decrease) in cash and cash equivalents | 2,384,406 | -578,540 | -2,809,604 |
| Cash and cash equivalents - beginning of period | 3,379,212 | 6,767,356 | - |
| Cash and cash equivalents - end of period | 5,763,618 | 3,379,212 | - |
Pharma-Bio Serv, Inc. (PBSV)
Pharma-Bio Serv, Inc. (PBSV)